The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

about

ASGR1 - a new target for lowering non-HDL cholesterol.FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors.

P2860

Q42378614-9D03CD30-DA53-45FD-B1F6-2AFF77A262AF Q55260525-92E48CFD-1833-4587-B500-0CF1F88F2540

P2860

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

Item

http://www.wikidata.org/entity/Q42367561

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@en

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@nl

type

Item

label

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@en

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@nl

prefLabel

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@en

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@nl

P1476

The PCSK9 revolution and the p ...... ies to reduce LDL-cholesterol.

@en

P2860

ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

P304

e201702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21542/GCSP.2017.2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Nabil G Seidah

P577

2017-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28971102

http://www.w3.org/2001/XMLSchema#string

P932

5621713

http://www.w3.org/2001/XMLSchema#string

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

about

P2860

P2860

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932